However, emerging evidence suggests that GLP-1RAs could be beneficial for specific eating disorder symptoms in individuals with obesity who do not have diabetes, potentially reducing binge eating, dietary disinhibition, overall eating disorder psychopathology, and concerns about body shape (Chao et al., 2019)
Patients who experience sudden vision loss should stop taking the drugs and see a doctor immediately, Katz advised
Additionally, from March 1, 2013, to December 31, 2022, patients prescribed SGLT2 inhibitors in the GLP-1 RAs cohort and vice versa were excluded
Evidence suggests that GLP-1 receptor agonists can effectively reduce visceral adipose tissue, though the degree to which this reduction is preferential compared to subcutaneous fat continues to be investigated